Premium
Babesia bovis: comparison of culture‐derived parasites, non‐living antigen and conventional vaccine in the protection of cattle against heterologous challenge
Author(s) -
TIMMS P.,
DALGLIESH R. J.,
BARRY D. N.,
DIMMOCK C. K.,
RODWELL B. J.
Publication year - 1983
Publication title -
australian veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.382
H-Index - 59
eISSN - 1751-0813
pISSN - 0005-0423
DOI - 10.1111/j.1751-0813.1983.tb05874.x
Subject(s) - heterologous , biology , babesia bovis , vaccination , antigen , virology , babesia , antibody , babesiosis , adjuvant , microbiology and biotechnology , immunoassay , veterinary medicine , immunology , medicine , biochemistry , gene
SUMMARY Twenty Bos taurus cattle were vaccinated with either live commercial Babesia bovis vaccine, live parasites from in vitro culture or non‐living supernatant antigen (NLSA) derived from in vitro culture and combined with the adjuvant saponin. Heterologous strain challenge 10 weeks later indicated that cattle vaccinated with live parasites from either source were strongly protected, those given 2 doses of NLSA 2 weeks apart were partially protected, and those given one dose of NLSA were poorly protected. Enzyme immunoassay detected comparable, increasing levels of specific babesial antibody in all vaccinated cattle during the 2 to 3 weeks following vaccination, after which levels in cattle given NLSA decreased. Antibody to bovine blood group factors was detected in 4 of the 10 animals given NLSA. Titres peaked after 3 to 4 weeks and then declined rapidly.